Abraxis BioScience Initiates Patient Enrollment in Phase II Study of Coroxane(TM) for Prevention of Restenosis in Peripheral Vascular Disease

LOS ANGELES, Apr 02, 2008 (BUSINESS WIRE) -- Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced it has initiated enrollment in its Phase II clinical trial to evaluate the efficacy and safety of Coroxane(TM: 97.98, -2.06, -2.05%) for the prevention and reduction of restenosis following revascularization of the superficial femoral artery (SFA).
Coroxane(TM: 97.98, -2.06, -2.05%) (nanometer-sized paclitaxel, ABRAXANE(R: 62.96, -1.36, -2.11%), under the trade name Coroxane(TM: 97.98, -2.06, -2.05%)) is a novel, solvent free, albumin-bound form of paclitaxel used for cardiovascular applications. ABRAXANE(R: 62.96, -1.36, -2.11%) is the first and only approved protein-bound nanometer-sized solvent-free taxane and is the first commercial product to validate Abraxis' proprietary nab(TM: 97.98, -2.06, -2.05%) technology platform. ABRAXANE(R: 62.96, -1.36, -2.11%) (for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)) is marketed for the treatment of breast cancer.

full article >> http://www.foxbusiness.com/markets/industries/health-care/article/abraxis-bioscience-initiates-patient-enrollment-phase-ii-study-coroxanetm_544886_10.html